When pricing remains a headwind for cholesterol-decreasing drug Repatha, sales continue to rose 31% while in the quarter as desire ongoing to increase at a rapid pace.I think It might be hard to actually get down both, Unless of course there was some drastic reduction in provide or a large basic safety issue that we somehow didn’t see right until